Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.220.595 |
Chemical and physical data | |
Formula | C8H14N2O |
Molar mass | 154.213 g·mol |
3D model (JSmol) | |
SMILES
|
Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.
- Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.
See also
References
- Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–882. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.
- Broadley KJ, Kelly DR (2001). "Muscarinic Receptor Agonists and Antagonists". Molecules. 6 (3): 142–193. doi:10.3390/60300142. ISSN 1420-3049. PMC 6236374.
Psychoanaleptics: Anti-dementia agents (ATC code N06D and others) | |
---|---|
AChE inhibitor medications | |
Other medications | |
Experimental BACE inhibitors |